ESTA Quote, Financials, Valuation and Earnings

Agenus, Inc. has a net margin of -4.05% compared to Establishment Labs Holdings, Inc.'s net margin of -116.82%. Establishment Labs Holdings, Inc.'s return on equity of -165.45% beat Agenus, Inc.'s return on equity of --.

Establishment Labs Holdings, Inc. has a consensus price target of $89.78, signalling upside risk potential of 26.2%. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 285.42%. Given that Agenus, Inc. has higher upside potential than Establishment Labs Holdings, Inc., analysts believe Agenus, Inc. is more attractive than Establishment Labs Holdings, Inc..

Establishment Labs Holdings, Inc. has a beta of 0.914, which suggesting that the stock is 8.575% less volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.567, suggesting its more volatile than the S&P 500 by 56.664%.

Establishment Labs Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Establishment Labs Holdings, Inc. pays -- of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend.

Establishment Labs Holdings, Inc. quarterly revenues are $64.6M, which are larger than Agenus, Inc. quarterly revenues of $30.2M. Establishment Labs Holdings, Inc.'s net income of -$2.6M is lower than Agenus, Inc.'s net income of $63.9M. Notably, Establishment Labs Holdings, Inc.'s price-to-earnings ratio is -- while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Establishment Labs Holdings, Inc. is 9.93x versus 0.81x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Agilon Health, Inc. has a net margin of -4.05% compared to Establishment Labs Holdings, Inc.'s net margin of -12.04%. Establishment Labs Holdings, Inc.'s return on equity of -165.45% beat Agilon Health, Inc.'s return on equity of -111.79%.

Establishment Labs Holdings, Inc. has a consensus price target of $89.78, signalling upside risk potential of 26.2%. On the other hand Agilon Health, Inc. has an analysts' consensus of $0.94 which suggests that it could grow by 35.17%. Given that Agilon Health, Inc. has higher upside potential than Establishment Labs Holdings, Inc., analysts believe Agilon Health, Inc. is more attractive than Establishment Labs Holdings, Inc..

Establishment Labs Holdings, Inc. has a beta of 0.914, which suggesting that the stock is 8.575% less volatile than S&P 500. In comparison Agilon Health, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Establishment Labs Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agilon Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Establishment Labs Holdings, Inc. pays -- of its earnings as a dividend. Agilon Health, Inc. pays out -- of its earnings as a dividend.

Establishment Labs Holdings, Inc. quarterly revenues are $64.6M, which are smaller than Agilon Health, Inc. quarterly revenues of $1.6B. Establishment Labs Holdings, Inc.'s net income of -$2.6M is higher than Agilon Health, Inc.'s net income of -$188.9M. Notably, Establishment Labs Holdings, Inc.'s price-to-earnings ratio is -- while Agilon Health, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Establishment Labs Holdings, Inc. is 9.93x versus 0.05x for Agilon Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Alnylam Pharmaceuticals, Inc. has a net margin of -4.05% compared to Establishment Labs Holdings, Inc.'s net margin of 16.99%. Establishment Labs Holdings, Inc.'s return on equity of -165.45% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.

Establishment Labs Holdings, Inc. has a consensus price target of $89.78, signalling upside risk potential of 26.2%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 39.63%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than Establishment Labs Holdings, Inc., analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than Establishment Labs Holdings, Inc..

Establishment Labs Holdings, Inc. has a beta of 0.914, which suggesting that the stock is 8.575% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.361, suggesting its less volatile than the S&P 500 by 63.901%.

Establishment Labs Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Establishment Labs Holdings, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Establishment Labs Holdings, Inc. quarterly revenues are $64.6M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Establishment Labs Holdings, Inc.'s net income of -$2.6M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Establishment Labs Holdings, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 145.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Establishment Labs Holdings, Inc. is 9.93x versus 11.76x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Savara, Inc. has a net margin of -4.05% compared to Establishment Labs Holdings, Inc.'s net margin of --. Establishment Labs Holdings, Inc.'s return on equity of -165.45% beat Savara, Inc.'s return on equity of -78.83%.

Establishment Labs Holdings, Inc. has a consensus price target of $89.78, signalling upside risk potential of 26.2%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 92.39%. Given that Savara, Inc. has higher upside potential than Establishment Labs Holdings, Inc., analysts believe Savara, Inc. is more attractive than Establishment Labs Holdings, Inc..

Establishment Labs Holdings, Inc. has a beta of 0.914, which suggesting that the stock is 8.575% less volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.311, suggesting its less volatile than the S&P 500 by 68.931%.

Establishment Labs Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Establishment Labs Holdings, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.

Establishment Labs Holdings, Inc. quarterly revenues are $64.6M, which are larger than Savara, Inc. quarterly revenues of --. Establishment Labs Holdings, Inc.'s net income of -$2.6M is higher than Savara, Inc.'s net income of -$29.6M. Notably, Establishment Labs Holdings, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Establishment Labs Holdings, Inc. is 9.93x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.